Skip to main content

Table 1 demographic, clinical and laboratory characteristics of the eight HIV+ individuals at baseline and session 2

From: Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study

Baseline

Patients

VPA

HIV duration

Nadir CD4

Current CD4

Log Plasma VL

VL 50 cp/mL

Year of 1st HAART

Past HIV-CNS

Depressive complaints

1.00

1

11.00

90.00

580.00

1.69

undetectable

1996.00

1

mild

2.00

0

16.00

14.00

187.00

2.70

detectable

1996.00

1

mild

3.00

0

5.00

144.00

220.00

1.69

undetectable

1996.00

0

moderate

4.00

1

11.00

42.00

858.00

1.69

undetectable

1998.00

1

none

5.00

1

16.00

10.00

16.00

5.28

detectable

1996.00

1

moderate

6.00

1

9.00

25.00

220.00

1.69

undetectable

1997.00

0

mild

7.00

1

2.00

50.00

450.00

1.70

undetectable

2000.00

0

moderate

8.00

1

17.00

5.00

410.00

2.23

detectable

2000.00

1

none

Session 2

Patients

VPA

Current CD4

Log Plasma VL

VL 50 cp/mL

Depressive complaints

VPA session 3

VPA session 4

  

1.00

1

683.00

1.70

undetectable

moderate

-

-

  

2.00

1

204.00

2.60

detectable

none

0

1

  

3.00

1

240.00

1.69

undetectable

moderate

1

0

  

4.00

1

864.00

2.60

detectable

none

-

-

  

5.00

1

90.00

4.91

detectable

moderate

-

-

  

6.00

1

252.00

2.60

detectable

severe

1

1

  

7.00

1

460.00

1.69

undetectable

mild

1

   

8.00

1

260.00

1.69

undetectable

severe

0

0